Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

NCT05487599 is registered in ClinicalTrials.gov with Prevail Therapeutics as lead sponsor.

NCT NCT05487599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05487599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
Lead sponsor
Prevail Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 20, 2022
Completion date
August 30, 2031
Enrollment
8 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, gaucher disease, type 1